GlobeNewswire: MannKind Contains the last 10 of 306 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:09:00ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/26/2852734/0/en/MannKind-Announces-CFO-Transition.html?f=22&fvtc=4&fvtv=20762MannKind Announces CFO Transition2024-03-26T20:05:00Z<![CDATA[DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Steven B. Binder will retire from his position as Chief Financial Officer, effective April 22, 2024. Mr. Binder plans to remain at MannKind through the end of the year as Executive Vice President, Special Projects.]]>https://www.globenewswire.com/news-release/2024/03/11/2843565/0/en/INHALE-3-Study-s-Initial-Meal-Challenge-Results-Comparing-Afrezza-Head-To-Head-With-Multiple-Daily-Injections-MDI-and-Insulin-Pumps.html?f=22&fvtc=4&fvtv=20762INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps 2024-03-11T10:05:00Z<![CDATA[DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced initial meal challenge data from INHALE-3 that was presented by Dr. Irl B. Hirsch at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence on March 8th. INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.]]>https://www.globenewswire.com/news-release/2024/03/05/2840233/0/en/MannKind-Announces-New-Clinical-Data-From-Inhale-3-Study-to-be-Presented-by-Dr-Irl-B-Hirsch-at-ATTD-on-March-8.html?f=22&fvtc=4&fvtv=20762MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 82024-03-05T11:05:00Z<![CDATA[Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder) Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)]]>https://www.globenewswire.com/news-release/2024/03/04/2839910/0/en/MannKind-Corporation-Announces-Participation-at-Upcoming-Conferences.html?f=22&fvtc=4&fvtv=20762MannKind Corporation Announces Participation at Upcoming Conferences2024-03-04T18:01:00Z<![CDATA[WESTLAKE VILLAGE, Calif. and DANBURY, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences.]]>https://www.globenewswire.com/news-release/2024/02/27/2836412/0/en/MannKind-Corporation-Reports-2023-Fourth-Quarter-and-Full-Year-Financial-Results-Provides-Clinical-Development-Update.html?f=22&fvtc=4&fvtv=20762MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update2024-02-27T21:00:00Z<![CDATA[Conference Call to Begin Today at 5:00 p.m. (ET) Conference Call to Begin Today at 5:00 p.m. (ET)]]>https://www.globenewswire.com/news-release/2024/02/20/2831617/0/en/MannKind-Corporation-to-Hold-2023-Fourth-Quarter-and-Full-Year-Financial-Results-Conference-Call-on-February-27-2024.html?f=22&fvtc=4&fvtv=20762MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 20242024-02-20T11:00:00Z<![CDATA[DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, February 27, 2024.]]>https://www.globenewswire.com/news-release/2024/02/15/2829760/0/en/MannKind-Announces-Enrollment-Goal-Completion-of-INHALE-1-Pediatric-Diabetes-Trial-Utilizing-Afrezza.html?f=22&fvtc=4&fvtv=20762MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®2024-02-15T11:05:00Z<![CDATA[DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has fully enrolled 305 patients living with type 1 or type 2 diabetes in its INHALE-1 study assessing efficacy and safety of inhaled insulin in the pediatric population.]]>https://www.globenewswire.com/news-release/2024/01/02/2802534/0/en/MannKind-and-Sagard-Healthcare-Enter-Into-Royalty-Purchase-Agreement-for-Up-to-200-Million.html?f=22&fvtc=4&fvtv=20762MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million2024-01-02T11:05:00Z<![CDATA[WESTLAKE VILLAGE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that on December 27, 2023 it sold a 1% royalty in net sales of Tyvaso DPI® (treprostinil) inhalation powder in exchange for up to $200 million, including the purchase price of $150 million and an additional potential milestone payment of up to $50 million.]]>https://www.globenewswire.com/news-release/2023/12/28/2801628/0/en/MannKind-Corporation-to-Present-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=20762MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference2023-12-28T11:00:00Z<![CDATA[DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 11:15 AM PST at the Westin St. Francis Hotel in San Francisco, California.]]>https://www.globenewswire.com/news-release/2023/11/07/2775536/0/en/MannKind-Corporation-Reports-2023-Third-Quarter-Financial-Results.html?f=22&fvtc=4&fvtv=20762MannKind Corporation Reports 2023 Third Quarter Financial Results2023-11-07T21:00:00Z<![CDATA[Conference Call to Begin Today at 5:00 p.m. (ET)]]>